Dysregulation of secretion of CXC α-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-γ agonists

In papillary thyroid carcinomas (PTCs), oncogenes activate a transcriptional program including the upregulation of CXCL10 chemokine. which stimulates proliferation and invasion Furthermore, peroxisome proliferator-activated receptor-gamma (PPAR gamma) activators thiazolidinediones (TZDs) modulate CXCL10 secretion in normal thyroid follicular cells (TFC), and inhibit PTC growth Until now, no study has evaluated the effect of cytokines on CXCL10 secretion in PTCs, nor the effect of PPAR gamma activation. The combined effects of interferon gamma (IFN gamma) and tumor necrosis factor alpha (TNF alpha) stimulation on CXCL10 secretion in primary cells from PTCs and TFC were tested Furthermore, the effect of PPAR gamma activation by TZIDs, on CXCL10 secretion and proliferation in these cell types was studied In primary cultures of TFC and PTCs CXCL10 production was absent under basal conditions, a similar dose-dependent secretion of CXCL10 was induced by IFN gamma in both cell types TNF alpha alone induced a slight but significant CXCL10 secretion only in PTCs. The stimulation with IFN gamma+TNF alpha induced a synergistic CXCL10 release in both cell types, however, a secretion more than ten times higher was induced in PTCs Treatment of TFC with TZDs dose-dependently suppressed IFN gamma+TNF alpha-induced CXCL10 release, while TZDs stimulated CXCL10 secretion in PTCs. A significant antiproliferative effect by TZDs was observed only in PTCs. In conclusion, a dysregulation of CXCL10 secretion has been shown in PTCs In fact, a CXCL10 secretion more than ten times higher has been induced by IFN gamma+TNF alpha in PTCs with respect to TFC. Moreover, TZDs inhibited CXCL10 secretion in TFC and stimulated it in PTCs. The effect of TZDs on CXCL10 was unrelated to the significant antiproliferative effect in PTCs Endocrine-Related Cancer (2009) 16 1299-1311